12:00 AM
May 17, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SCH 58500: Began Phase II testing

Schering-Plough Research Institute, Kenilworth, N.J.
Product: SCH 58500
Business: Cancer, Gene/Cell therapy
Therapeutic category: Gene...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >